Skip to main content

H.R. 2805

Referred to Committee

Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015

Introduced 6/17/2015•114th Congress•House

Latest Action

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

7/9/2015 • House

Summary

Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015

This bill requires the Department of Health and Human Services (HHS), in cooperation with the Department of Veterans Affairs, the Department of Defense, and the Drug Enforcement Administration (DEA), to convene a Pain Management Best Practices Inter-Agency Task Force to develop and study best practices for pain management and prescription of pain medication.

This bill amends the Public Health Service Act to revise and extend through FY2020 the controlled substance monitoring program.

Government entities receiving nonidentifiable information from a controlled substance monitoring database for research purposes may make that information available to other entities for research purposes.

A state receiving a grant for a controlled substance monitoring program must: (1) facilitate prescriber and dispenser use of the state's controlled substance monitoring system, and (2) educate prescribers and dispensers on the benefits of the system.

This bill amends the Omnibus Crime Control and Safe Streets Act of 1968 to extend the Edward Byrne Memorial Justice Assistance Grant Program through FY2020.

HHS must advance education and awareness of the risk of abuse of prescription opioids (drugs with effects similar to opium).

The Office of National Drug Control Policy (ONDCP), in coordination with HHS and the DEA, must establish a national drug awareness campaign that emphasizes the similarities between heroin and prescription opioids.

The DEA, in coordination with HHS and ONDCP, may make grants to state, local, or tribal governments to create demonstration programs to allow first responders to prevent opioid overdose death by administering an opioid overdose reversal drug (e.g., naloxone).

Introduced in House • 6/17/2015

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health
Advisory bodiesCivil actions and liabilityCongressional oversightCrime preventionDrug therapyDrug trafficking and controlled substancesDrug, alcohol, tobacco useEmergency medical services and trauma careFirst responders and emergency personnelGovernment information and archivesHealth information and medical recordsHealth programs administration and fundingHealth promotion and preventive careLaw enforcement administration and fundingMedical researchPrescription drugsState and local government operations

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (47)

Party Breakdown

20
Democrats
27
Republicans
0
Independents

Sponsor

R[
Rep. Brooks, Susan W. [R-IN-5]

Republican • IN-5

Sponsored 6/17/2015

Cosponsors (46)

R[
Rep. Carson, André [D-IN-7]

D-IN-7

Joined 6/17/2015

R[
Rep. Walorski, Jackie [R-IN-2]

R-IN-2

Joined 6/17/2015

R[
Rep. Whitfield, Ed [R-KY-1]

R-KY-1

Joined 6/17/2015

R[
Rep. Messer, Luke [R-IN-6]

R-IN-6

Joined 6/17/2015

R[
Rep. Kuster, Ann M. [D-NH-2]

D-NH-2

Joined 6/18/2015

Bill Journey

Originated in the House

Introduced

June 17, 2015

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in House6/17/2015

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors46